Literature DB >> 24852920

Changes in cognition, arm function and lower body function after slow-release Fampridine treatment.

Hb Jensen1, M Ravnborg2, S Mamoei3, U Dalgas4, E Stenager5.   

Abstract

OBJECTIVE: We aimed to evaluate the effect of slow-release (SR) Fampridine on multiple outcome measures reflecting different domains, and to compare the responsiveness of the Six Spot Step Test (SSST) and the Timed 25 Foot Walk (T25FW).
METHODS: For this study 108 participants were included. On day 0 they were tested with the T25FW, the SSST, the 9-Hole Peg Test (9-HPT), the 5 Times Sit-To-Stand test (5-STS) and the Symbol Digit Modalities Test (SDMT). Four weeks of treatment with SR Fampridine 10 mg BID was commenced. Participants were tested again after 26-28 days of treatment.
RESULTS: Mean changes observed were: SSST -3.4±6.4 s (p<0.001), T25FW -1.2±3.7 s (p<0.001), 9-HPT -1.2±6.0 s (p<0.001), 5- STS -3.4±7.2 s (p<0.001) and SDMT 1.4±4.8 a.u. (p=0.003). Change on the SSST differed significantly from T25FW (SSST 17.0±19.6% vs. T25FW 11.2±17.1%, p=0.0013). Some 48.6% were found to have a meaningful change on the SSST compared with 25.7% on the T25FW. The response to treatment with SR Fampridine did not correlate with age, sex, Expanded Disability Status Scale and disease duration.
CONCLUSION: SR Fampridine treatment has significant effects on different domains including upper and lower body and cognition. Furthermore, the SSST is more responsive to the effect of SR Fampridine than is the T25FW. ClinicalTrials.gov identifier: NCT01656148.
© The Author(s), 2014.

Entities:  

Keywords:  Multiple sclerosis; axonal loss; demyelination; rehabilitation

Mesh:

Substances:

Year:  2014        PMID: 24852920     DOI: 10.1177/1352458514533844

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

1.  Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.

Authors:  Etienne Allart; Anne Benoit; Anne Blanchard-Dauphin; Vincent Tiffreau; André Thevenon; Hélène Zephir; Olivier Outteryck; Arnaud Lacour; Patrick Vermersch
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

2.  Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.

Authors:  Sarah D Broicher; Linard Filli; Olivia Geisseler; Nicole Germann; Björn Zörner; P Brugger; M Linnebank
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

Review 3.  Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.

Authors:  Esther S Kim
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

4.  Development of a PET radioligand for potassium channels to image CNS demyelination.

Authors:  Pedro Brugarolas; Jorge E Sánchez-Rodríguez; Hsiu-Ming Tsai; Falguni Basuli; Shih-Hsun Cheng; Xiang Zhang; Andrew V Caprariello; Jerome J Lacroix; Richard Freifelder; Dhanabalan Murali; Onofre DeJesus; Robert H Miller; Rolf E Swenson; Chin-Tu Chen; Peter Herscovitch; Daniel S Reich; Francisco Bezanilla; Brian Popko
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

5.  Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Authors:  Robert W Motl; Jeffrey A Cohen; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312

6.  Dalfampridine effects on cognition, fatigue, and dexterity.

Authors:  Melanie Korsen; Rhina Kunz; Ulf Schminke; Uwe Runge; Thomas Kohlmann; Alexander Dressel
Journal:  Brain Behav       Date:  2016-11-11       Impact factor: 2.708

7.  Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.

Authors:  Francisco Alejandro Rodriguez-Leal; Rocco Haase; Katja Akgün; Judith Eisele; Undine Proschmann; Thorsten Schultheiss; Raimar Kern; Tjalf Ziemssen
Journal:  Ther Adv Chronic Dis       Date:  2019-04-19       Impact factor: 5.091

8.  Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.

Authors:  Michelle H Chen; Yael Goverover; Helen M Genova; John DeLuca
Journal:  CNS Drugs       Date:  2020-06       Impact factor: 5.749

9.  Structure-activity relationship studies of four novel 4-aminopyridine K+ channel blockers.

Authors:  Sofia Rodríguez-Rangel; Alyssa D Bravin; Karla M Ramos-Torres; Pedro Brugarolas; Jorge E Sánchez-Rodríguez
Journal:  Sci Rep       Date:  2020-01-09       Impact factor: 4.379

10.  Fampridine and quality of life in individuals with multiple sclerosis.

Authors:  Yoshimasa Sagawa; Eloi Magnin; Laura Paillot; Thierry Moulin; Pierre Decavel
Journal:  Springerplus       Date:  2016-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.